respiratori
diseas
common
caus
human
ill
acut
respiratori
infect
caus
mainli
virus
lead
caus
medic
consult
countri
respons
work
absenc
develop
countri
respiratori
ill
respons
death
million
children
per
year
averag
preschool
children
encount
episod
respiratori
ill
per
year
experi
symptom
year
adult
usual
experi
episod
period
approxim
virus
involv
includ
order
import
influenza
respiratori
syncyti
virus
rsv
rhinovirus
coronavirus
includ
sever
acut
respiratori
syndrom
sar
coronaviru
coxsackievirus
parainfluenza
virus
piv
human
metapneumovirus
hmpv
adenovirus
vaccin
avail
influenza
virus
countri
influenza
vaccin
administ
inactiv
whole
subunitsplit
viru
prepar
vaccin
contain
haemagglutinin
neuraminidas
surfac
antigen
influenza
virus
influenza
b
virus
order
vaccin
effect
antigen
must
updat
regularli
take
account
antigen
drift
seed
virus
use
prepar
inactiv
vaccin
consist
strain
grow
high
titr
case
influenza
virus
reassort
contain
surfac
antigen
gene
exist
strain
reprint
order
pleas
contact
reprint
ashleypubcom
gene
enhanc
growth
highyield
parent
viru
vaccin
virus
usual
grown
allanto
caviti
embryon
chicken
egg
concentr
purifi
zonal
centrifug
inactiv
treatment
formaldehyd
reactogen
associ
whole
virus
usual
remov
disrupt
deterg
split
vaccin
separ
nonsurfac
antigen
purifi
whole
viru
subunit
vaccin
mani
attempt
made
develop
vaccin
respiratori
virus
wide
believ
live
vaccin
administ
directli
respiratori
tract
offer
prospect
produc
much
broader
longlast
protect
parenter
administ
kill
vaccin
live
vaccin
induc
repertoir
igm
igg
local
secretori
iga
antibodi
cellmedi
respons
induc
natur
infect
vaccin
virus
replic
limit
extent
respiratori
tract
induc
respons
mani
epitop
possibl
nonrepl
antigen
potenti
advantag
mucos
compar
parenter
vaccin
immun
respons
induc
presenc
matern
antibodi
effect
live
vaccin
requir
use
virus
suitabl
attenu
time
immunogen
capabl
vitro
growth
econom
titr
vaccin
product
live
attenu
vaccin
influenza
recent
licens
restrict
use
us
use
russia
mani
year
concern
use
live
vaccin
face
new
pandem
relat
possibl
reassort
occur
gene
pandem
viru
live
influenza
vaccin
produc
viru
es
unpredict
virul
concern
much
diminish
interpandem
period
surfac
antigen
gene
epidem
vaccin
reassort
similar
inactiv
vaccin
requir
particular
issu
relat
work
safeti
aris
exampl
avian
strain
becom
endem
avian
speci
mani
region
asia
replac
virus
predomin
human
influenza
subtyp
mani
attempt
made
produc
live
viru
vaccin
respiratori
virus
use
tradit
techniqu
multipl
coldpassag
chemic
mutagenesi
attempt
develop
live
vaccin
pursu
failur
inactiv
vaccin
develop
notabl
attempt
develop
formalininactiv
vaccin
rsv
vaccin
infant
exhibit
enhanc
immunopatholog
follow
natur
rsv
challeng
similarli
attempt
develop
inactiv
vaccin
paramyxovirus
rhinovirus
unsuccess
sheer
number
rhinoviru
serotyp
signific
disincent
attempt
vaccin
develop
effort
aim
prevent
rhinovirus
direct
toward
develop
groupspecif
antivir
chemotherapeut
agent
similar
consider
appli
adenovirus
unlik
respiratori
virus
possess
doublestrand
dna
genom
howev
live
vaccin
serotyp
develop
institut
use
deliv
enter
capsul
respiratori
immun
develop
common
mucos
pathway
nonsar
coronavirus
import
role
aetiolog
common
cold
technic
difficult
grow
cell
cultur
consid
vaccin
develop
sar
coronaviru
hand
grow
readili
cell
cultur
inactiv
virus
shown
induc
high
level
neutralis
antibodi
balbc
mice
requir
cell
culturederiv
inactiv
vaccin
could
develop
prevent
measur
sar
pandem
influenza
virus
manufactur
process
repres
signific
biohazard
need
robust
measur
biolog
contain
potenti
pandem
influenza
strain
would
highli
desir
disarm
viru
specif
modifi
gene
associ
virul
revers
genet
review
concern
princip
new
approach
develop
vaccin
influenza
virus
rsv
paramyxovirus
negativestrand
rna
virusesbi
applic
revers
genet
revers
genet
allow
direct
manipul
cdna
copi
rna
genom
parent
virus
therebi
provid
mean
ration
attenu
virus
use
live
vaccin
candid
case
pandem
influenza
remov
virul
factor
allow
largescal
manufactur
inactiv
vaccin
condit
industri
safeti
term
revers
genet
use
defin
direct
modif
cdna
function
phenotyp
analysi
revers
genet
use
molecular
virolog
gener
infecti
virus
possess
genom
deriv
clone
cdna
modifi
order
studi
consequ
effect
phenotyp
first
revers
genet
system
describ
positivesens
rna
virus
transfect
fulllength
genom
rna
positivesens
rna
virus
eukaryot
cell
result
rna
act
mrna
translat
viral
protein
turn
infecti
viru
revers
genet
wide
use
vaccin
develop
viral
protein
interact
studi
recombin
protein
express
gene
therapi
contrast
genom
negativesens
rna
virus
messeng
function
noninfecti
initi
rna
transcript
viral
rna
requir
presenc
viral
ribonucleoprotein
rnp
complex
rnp
essenti
transcript
viral
rna
mrna
replic
viru
genom
role
rnp
first
shown
vesicular
stomat
viru
purifi
polymeras
protein
activ
presenc
virion
rnp
first
negativesens
rna
viru
gener
entir
cdna
describ
rabi
viru
cell
cotransfect
cdna
construct
encod
fulllength
rabi
viru
antigenom
l
p
n
proteinexpress
construct
control
rna
polymeras
recombin
vaccinia
viru
express
rna
polymeras
suppli
rna
polymeras
transcript
mrna
genom
rna
key
step
procedur
express
antigenom
rna
unabl
hybridis
mrna
encod
l
p
n
protein
group
use
cdna
construct
express
positivesens
crna
rescu
sendai
human
piv
hpiv
ebola
virus
although
lower
effici
rescu
positivesens
cdna
transfect
contrast
rescu
segment
negativesens
rna
virus
difficult
first
demonstr
rescu
segment
negativesens
rna
viru
entir
cdna
achiev
bunyamwera
viru
shortli
thereaft
influenza
virus
rsv
revers
genet
system
describ
collin
et
al
compris
cdna
copi
rsv
antigenom
rna
polymeras
promot
end
hammerhead
ribozym
rna
polymeras
transcript
termin
end
hammerhead
ribozym
sequenc
includ
allow
correct
cleavag
end
antigenom
strategi
product
recombin
infecti
viru
cdna
use
system
involv
express
antigenom
togeth
coexpress
n
p
l
includ
rsv
hmpv
protein
protein
necessari
synthesi
antigenom
rna
genom
rna
templat
transfect
cell
simultan
infect
modifi
vaccinia
ankara
viru
express
rna
polymeras
strain
use
host
rangerestrict
mutant
replic
effici
cell
avian
origin
mammalian
cell
block
late
stage
virion
matur
significantli
reduc
yield
infecti
viru
viru
yield
system
low
although
suffici
recoveri
viru
passag
gener
influenza
virus
revers
genet
far
complex
negativestrand
virus
eight
vrna
segment
four
differ
viral
protein
involv
furthermor
viral
rna
replic
transcript
occur
nuclei
influenza
virusinfect
cell
vitro
gener
vrnp
transfect
cell
must
transport
nucleu
develop
method
rescu
influenza
virus
clone
cdna
refin
past
decad
point
possibl
rescu
influenza
entir
clone
cdna
system
report
neumann
et
al
cdna
eight
genom
segment
clone
neg
orient
human
rna
polymeras
promot
mous
rna
polymeras
termin
transfect
eight
plasmid
humanderiv
cell
line
line
result
vrna
synthesi
cellular
rna
polymeras
eight
rnaproduc
plasmid
togeth
nine
proteinexpress
plasmid
pa
ha
np
na
cotransfect
cell
yield
plaqu
form
unit
pfu
ml
viru
produc
within
h
helper
viru
requir
gener
recombin
viru
cumbersom
select
process
describ
earlier
studi
involv
rnp
necessari
similar
titr
also
report
follow
transfect
eight
rnaproduc
plasmid
four
proteinexpress
plasmid
pa
np
figur
similar
approach
taken
fodor
et
al
insert
cdna
copi
eight
genom
segment
human
rna
polymeras
promot
hepat
delta
viru
ribozym
plasmid
togeth
nine
proteinexpress
plasmid
transfect
vero
cell
yield
cell
obtain
within
day
improv
system
report
hoffmann
et
al
eight
plasmid
requir
plasmid
contain
cdna
genom
segment
clone
posit
orient
human
rna
polymeras
promot
end
mous
rna
polymeras
termin
end
upstream
rna
polymeras
termin
cytomegaloviru
cmv
immediateearli
promot
downstream
polyadenyl
sequenc
system
eight
plasmid
transfect
mix
cultur
cell
requir
human
rna
polymeras
mdck
cell
cellular
rna
polymeras
transcrib
cdna
vrna
cmv
promot
drive
protein
express
clone
express
viral
protein
vrna
assembl
bud
cell
membran
progeni
viru
progeni
virus
infect
mdck
cell
replic
produc
yield
pfuml
within
h
develop
techniqu
manipul
influenza
viru
gene
possibl
prepar
live
influenza
donor
strain
specif
properti
attenu
mani
exampl
exist
literatur
small
chang
genom
led
chang
virul
viru
one
exampl
specif
chang
lead
attenu
exchang
promot
region
na
gene
influenza
viru
influenza
b
gene
chang
produc
viru
attenu
mice
anoth
approach
could
use
insert
sever
attenu
mutat
natur
attenu
virus
donor
strain
revers
genet
produc
viru
suffici
attenu
genet
stabl
use
revers
genet
possibl
creat
virus
contain
delet
specif
gene
stabl
singl
base
chang
seen
ts
ca
virus
prepar
growth
reduc
temperatur
exampl
influenza
protein
abil
inhibit
host
antivir
interferon
respons
virus
lack
entir
gene
suscept
interferon
respons
shown
highli
attenu
mice
howev
mutant
larg
delet
may
overattenu
less
immunogen
human
replic
suffici
well
respiratori
tract
altern
approach
may
use
virus
truncat
protein
virus
express
ntermin
amino
acid
shown
possess
intermedi
interferoninhibit
properti
mice
may
suitabl
use
vaccin
donor
strain
anoth
promis
approach
use
delet
mutant
gene
elimin
gene
lead
replicationdefect
viru
grow
effici
cell
cultur
poorli
mice
anoth
approach
develop
brownle
group
oxford
use
altern
base
pair
conserv
vrna
promot
region
chang
conserv
base
revers
genet
give
rise
viru
attenu
attenu
demonstr
pa
na
ns
genom
segment
would
expect
lead
viru
attenu
introduc
eight
genom
segment
mutat
may
use
develop
donor
strain
use
live
vaccin
revers
genet
influenza
also
potenti
simplifi
process
shorten
time
requir
inactiv
vaccin
prepar
influenza
virus
use
consist
reassort
highyield
donor
strain
current
epidem
strain
reassort
usual
prepar
coinfect
egg
eggadapt
prepar
current
epidem
strain
donor
strain
progeni
viru
screen
presenc
reassort
contain
ha
na
epidem
strain
intern
gene
highyield
parent
specifi
high
growth
procedur
timeconsum
unpredict
coinfect
egg
two
differ
virus
could
theori
gener
differ
type
reassort
comprehens
screen
procedur
must
undertaken
select
desir
reassort
use
vaccin
seed
process
take
week
timelin
vaccin
prepar
gener
tight
primarili
depend
number
embryon
egg
requir
growth
vaccin
viru
egg
suppli
must
anticip
mani
month
advanc
potenti
problem
interrupt
suppli
problem
vaccin
manufactur
major
effect
timelin
vaccin
deliveri
method
use
revers
genet
describ
schickli
et
al
involv
transfect
eight
rna
express
plasmid
contain
ha
na
gene
epidem
strain
four
protein
express
plasmid
contain
pa
np
gene
prepar
viru
plasmid
use
transfect
cocultur
mdck
cell
line
progeni
virus
possess
surfac
antigen
epidem
strain
intern
gene
donor
ie
construct
similar
growth
properti
virus
prepar
convent
reassort
egg
use
donor
strain
hoffmann
et
al
describ
modifi
method
viru
rescu
requir
transfect
mdck
cocultur
eight
plasmid
rescu
virus
grew
high
titr
embryon
egg
surfac
antigen
parent
epidem
strain
main
disadvantag
applic
revers
genet
lie
use
mdck
cell
line
transform
human
cell
line
concern
suitabl
mdck
line
seem
unlik
either
would
licens
use
substrat
prepar
human
vaccin
moreov
human
rna
polymeras
promot
use
cell
human
primat
origin
ozaki
et
al
investig
possibl
use
cell
vero
line
transfect
vero
line
deriv
kidney
cell
african
green
monkey
licens
prepar
sever
human
viru
vaccin
includ
use
prevent
poliomyel
rabi
cell
vero
line
support
growth
influenza
virus
presenc
trypsin
use
prepar
influenza
vaccin
vaccin
shown
elicit
compar
antibodi
respons
higher
cytotox
lymphocyt
respons
obtain
egggrown
vaccin
revers
genet
approach
vaccin
product
consid
essenti
event
pandem
caus
new
human
influenza
viru
human
infect
avian
influenza
strain
observ
influenza
subtyp
virus
associ
highli
pathogen
infect
highli
pathogen
strain
lethal
chicken
chicken
embryo
lethal
associ
presenc
multipl
basic
amino
acid
motif
adjac
cleavag
site
ha
glycoprotein
presenc
motif
increas
rang
target
organ
support
growth
virus
contain
endogen
proteas
unless
cleavag
site
remov
would
possibl
grow
vaccin
virus
embryon
egg
altern
method
cultiv
includ
cell
cultur
would
use
addit
largescal
growth
unmodifi
virus
constitut
potenti
public
health
problem
approach
produc
suitabl
vaccin
candid
highli
pathogen
influenza
strain
subbarao
et
al
webbi
et
al
produc
virus
revers
genet
multipl
basic
amino
acid
motif
remov
hong
kong
asian
virus
subtyp
respect
virus
prepar
modifi
ha
na
deriv
avian
strain
intern
gene
replic
high
titr
embryon
egg
virus
contain
delet
shown
attenu
compar
wildtyp
avian
parent
lethal
chicken
mice
subbarao
et
al
report
vaccin
mice
formalininactiv
prepar
mutant
reassort
viru
result
immun
respons
compar
formalininactiv
prepar
avian
parent
although
rsv
first
isol
attempt
far
produc
suitabl
vaccin
unsuccess
formalininactiv
rsv
firsv
vaccin
test
infant
children
found
poorli
protect
quit
unexpectedli
increas
frequenc
infect
enhanc
sever
rsv
ill
follow
subsequ
infect
observ
vaccin
individu
compar
unvaccin
children
purifi
nativ
f
g
glycoprotein
studi
potenti
vaccin
candid
protein
purifi
variou
express
system
use
mammalian
cell
insect
cell
bacteria
well
rsvinfect
mammalian
cell
cultur
use
immunoaffin
chromatograph
method
protein
vaccin
evalu
extens
studi
suggest
purifi
protein
vaccin
may
also
induc
alter
cell
respons
similar
firsv
develop
live
attenu
rsv
vaccin
began
use
convent
techniqu
multipl
passag
chemic
mutagenesi
promis
strain
coldpassag
rsv
strain
moder
attenu
strain
cprsv
strain
mutat
two
round
chemic
mutagenesi
produc
temperaturesensit
ts
mutant
strain
evalu
seroposit
seroneg
children
one
shown
suffici
attenu
undergo
test
rsvneg
infant
month
age
test
group
vaccin
infant
shed
moder
level
viru
develop
signific
rise
rsvspecif
iga
highli
resist
reinfect
second
dose
vaccin
viru
given
month
later
howev
one
infant
shed
low
amount
vaccin
viru
partial
loss
ts
phenotyp
loss
attenu
indic
attenu
mutat
unstabl
use
revers
genet
allow
gener
rsv
mutant
defin
molecular
chang
viral
genom
consequ
possibl
defin
genet
basi
attenu
exist
cprsv
cptsrsv
mutant
gener
vaccin
candid
genet
defin
mutat
approach
produc
mutant
contain
delet
nonessenti
gene
develop
highli
stabl
attenu
characterist
five
rsv
gene
sh
g
regard
almost
nonessenti
delet
silenc
littl
effect
viru
growth
cultur
delet
g
gene
one
major
neutralis
antigen
rsv
would
unlik
produc
suitabl
vaccin
strain
virus
lack
g
gene
shown
overattenu
mice
littl
viru
replic
occur
upper
respiratori
tract
addit
coldpassag
rsv
b
viru
result
delet
sh
g
orf
test
primat
clinic
trial
found
overattenu
seroneg
infant
delet
mutant
produc
differ
level
attenu
chimpanze
delet
either
sh
gene
produc
viru
less
attenu
delet
produc
virus
attenu
gene
delet
therefor
appear
promis
method
attenu
vaccin
develop
allow
possibl
combin
method
attenu
anoth
approach
express
cytokin
chemokin
gene
within
viru
genom
exampl
recombin
rsv
express
granulocytemacrophag
colonystimul
factor
intranas
inocul
mice
result
dramat
increas
pulmonari
dendrit
cell
macrophag
initi
attempt
produc
parainfluenza
viru
vaccin
involv
inactiv
virus
prepar
infect
embryon
egg
primari
monkey
kidney
cell
cultur
vaccin
shown
immunogen
children
induc
serum
hi
neutralis
antibodi
provid
protect
diseas
subunit
vaccin
prepar
hn
f
glycoprotein
isol
purifi
insect
cell
infect
recombin
baculovirus
express
hn
f
protein
also
evalu
immunis
cotton
rat
viral
glycoprotein
induc
satisfactori
level
neutralis
hi
fi
antibodi
provid
protect
intranas
challeng
howev
subunit
vaccin
test
human
nonhuman
primat
two
differ
approach
use
develop
live
hpiv
vaccin
first
involv
use
bovin
viru
natur
attenu
respiratori
tract
rhesu
monkey
chimpanze
clinic
trial
administ
intranas
infant
children
month
age
candid
vaccin
welltoler
appear
satisfactorili
attenu
induc
protect
antibodi
respons
infect
second
involv
cold
passag
virul
strain
promis
vaccin
candid
develop
passag
progress
reduc
temperatur
viru
coldadapt
temperaturesensit
attenu
hamster
monkey
human
clinic
evalu
infant
month
age
demonstr
candid
strain
suitabl
attenu
immunogen
develop
characteris
live
attenu
hpiv
vaccin
greatli
facilit
applic
revers
genet
allow
attenu
mutat
vaccin
differenti
spontan
mutat
approach
also
allow
modif
exist
strain
produc
improv
vaccin
candid
revers
genet
system
avail
compar
recent
consequ
vaccin
candid
consist
chimer
virus
prepar
f
hn
orf
replac
correspond
sequenc
result
chimer
virus
shown
immunogen
hamster
may
therefor
possibl
develop
polyval
vaccin
use
antigen
chimaera
prepar
backbon
addit
applic
revers
genet
hpiv
vaccin
develop
involv
construct
novel
mutat
attenu
exist
natur
c
v
protein
knockout
mutat
attenu
viru
growth
hamster
monkey
anoth
approach
construct
chimaera
contain
mixtur
intern
protein
gene
one
chimaera
np
orf
replac
result
viru
exhibit
hostrang
restrict
monkey
typic
issu
concern
intellectu
properti
right
potenti
restrict
wider
applic
revers
genet
prepar
vaccin
exampl
influenza
virus
overal
patent
right
revers
genet
assign
medimmun
inc
gaithersburg
usa
although
individu
compani
hold
subsidiari
right
individu
patent
patent
holder
allow
readi
access
technolog
research
indic
intend
claim
futur
royalti
commerci
use
vaccin
manufactur
addit
concern
relat
intellectu
properti
major
obstacl
use
vaccin
could
classif
certain
jurisdict
genet
modifi
organ
gmo
appli
vaccin
prepar
tradit
method
classif
vaccin
candid
gmo
could
mean
imposit
addit
safeti
test
releas
despit
difficulti
wide
believ
continu
threat
pandem
influenza
expand
need
prepar
influenza
vaccin
revers
genet
use
prepar
influenza
vaccin
seed
near
futur
vaccin
candid
respiratori
virus
prepar
revers
genet
probabl
test
human
within
next
year
revers
genet
although
still
rel
new
tool
manipul
negativestrand
rna
virus
wide
regard
great
potenti
prepar
vaccin
mani
common
respiratori
virus
revers
genet
system
allow
direct
modif
genom
negativestrand
rna
virus
provid
power
mean
studi
viru
replic
assembl
allow
function
viral
protein
studi
modif
delet
singl
multipl
gene
futur
applic
provid
much
inform
avail
present
role
individu
gene
virul
mechan
viral
pathogen
allow
ration
basi
select
live
vaccin
strain
use
past
select
often
base
pure
empir
criteria
inactiv
vaccin
influenza
revers
genet
could
use
precis
identifi
specif
sequenc
concern
enhanc
growth
vaccin
reassort
egg
cell
cultur
could
contribut
significantli
cost
avail
pandem
vaccin
howev
vaccin
produc
revers
genet
classifi
gmo
countri
extens
safeti
test
requir
much
debat
ensu
licens
human
use
paper
special
note
highlight
either
interest
consider
interest
reader
